CME Chief Says Firm Plans to Sue CFTC Over Perpetual Futures Approval

What to Know

• CME Chief Executive Terrence Duffy said the company plans to sue the U.S. Commodity Futures Trading Commission after it approved perpetual futures products.
• Duffy argued the approval may conflict with the Dodd-Frank Act’s definition of a swap versus a futures contract.
• He said products that involve two parties exchanging payments may be classified as swaps, not futures.
• Duffy said CME wants clearer rules before deciding whether to list its own perpetual futures contracts.
• The executive, who is set to step down next year, said the regulatory framework is not clear enough at present.

CME Pushes Back on CFTC Decision

Terrence Duffy said CME will move to sue the CFTC after the regulator approved perpetual futures products earlier this month, escalating a growing dispute over how these instruments should be classified and supervised.

Speaking to CNBC, Duffy said the approval should not stand under the Dodd-Frank Act because the products appear to resemble swaps more than futures contracts. His comments signal a direct challenge to the regulator’s interpretation of the market structure.

Dispute Centers on Swap Versus Futures Rules

Duffy said the law clearly separates swaps from futures and argued that instruments involving reciprocal payments between two parties are generally treated as swaps. If perpetual futures fit that description, he suggested, they would need to meet different market requirements than traditional futures products.

He added that CME would need to understand the “rules of the road” before considering whether to list perpetual futures itself. For now, he said those rules remain unclear, leaving firms uncertain about how the products should be offered and regulated.

What It Means for the Market

The dispute highlights the regulatory uncertainty surrounding perpetual futures as exchanges and market participants weigh whether these products belong in the futures arena or under swap oversight. CME’s legal challenge could help define how U.S. regulators treat the contracts going forward.

With Duffy nearing the end of his tenure, the company’s position also underscores how high the stakes are for exchange operators seeking clarity before launching new derivatives products. The outcome could influence broader trading access and compliance obligations across the market.

Frequently Asked Questions (FAQs)

What is CME objecting to?

CME is objecting to the CFTC’s approval of perpetual futures products, arguing the instruments may not qualify as futures under the law.

Why does Duffy say the products may be swaps?

He said contracts that involve two parties exchanging payments can fall under the definition of a swap, which carries different regulatory requirements.

Will CME list perpetual futures?

Duffy said CME would first need clearer rules before deciding whether to offer its own perpetual futures contracts.

Why does this matter for traders?

The classification determines which rules apply, including market access, compliance obligations, and how the products can be offered in the U.S.

Photo by Pixabay on Pexels